Metarrestin, a perinucleolar compartment inhibitor, effectively suppresses metastasis

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Metastasis is a primary driver of cancer mortality.
• Targeting the metastatic process requires novel therapeutic strategies.
• The perinucleolar compartment (PNC) is implicated in cancer cell metastatic behavior.

Purpose of the Study:

• To identify novel compounds that selectively target cancer metastasis.
• To investigate the therapeutic potential of metarrestin against metastatic cancer.

Main Methods:

• High-content screening of over 140,000 compounds using PNC as a phenotypic marker.
• In vitro invasion assays and in vivo mouse models of human cancer.
• Analysis of metarrestin's mechanism of action, including nucleolar structure, RNA polymerase I transcription, and eEF1A2 interaction.

Main Results:

• Metarrestin disassembles PNCs in various cancer cell lines.
• Metarrestin inhibits cancer cell invasion in vitro.
• Metarrestin suppresses metastatic development in three mouse cancer models.
• Metarrestin extends survival in a pancreatic cancer xenograft model with no organ toxicity.

Conclusions:

• Metarrestin disrupts nucleolar structure and inhibits RNA polymerase I transcription.
• Metarrestin shows therapeutic promise for treating metastatic cancer.
• Metarrestin represents a potential new drug targeting cancer spread.